Trial Profile
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Jan 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 05 Jan 2023 Planned End Date changed from 1 Nov 2022 to 1 Nov 2024.
- 05 Jan 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2023.
- 05 Jan 2023 Status changed from recruiting to active, no longer recruiting.